Clinical Trial News and Research

RSS

New clinical trial: Pycnogenol improves signs and symptoms of menopause

Half the population experiences menopause, and for those women, it is a condition they will experience for approximately one third of their lifetime. Alternative or natural remedies are an easy, effective way to improve signs and symptoms linked to the menopausal transition, without side effects.

7 Mar 2012

Physicians study human stem cell use as possible treatment for ischemic stroke

Physicians at the Methodist Neurological Institute are studying the use of human stem cells as a possible treatment for acute ischemic stroke, a leading cause of death and disability. Each year, stroke affects more than 15 million people around the world.

7 Mar 2012

Ivabradine could save thousands of heart failure patients

Researchers behind a major trial of Procoralan believe the pill could save 10,000 lives a year in Britain alone. Ivabradine works by slowing the beating of the heart, helping it to pump blood more efficiently.

7 Mar 2012

Shire to commence two Vyvanse and Concerta Phase 4 comparison trials for ADHD

As part of its continued commitment to ADHD research, Shire plc, the global specialty biopharmaceutical company, today announced it is initiating two Phase 4 clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta (methylphenidate HCl) Extended-Release Tablets.

7 Mar 2012

MTPC, Medicago partner to develop and commercialize three new vaccines

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the establishment of a strategic alliance with Mitsubishi Tanabe Pharma Corporation (MTPC) through the execution of a Master Research Collaboration Agreement.

6 Mar 2012

Medidata net revenues increase 11% to $184.5M for full year 2011

Medidata Solutions, a leading global provider of SaaS clinical technology solutions that enhance the efficiency of clinical development, today announced its financial results for the fourth quarter and full year 2011, and provided detailed financial guidance for the first quarter and full year 2012.

6 Mar 2012

Gamma Knife vs. craniotomy to treat epilepsy

For about 25 percent of patients suffering from epilepsy, medications do not effectively control the disease and stop seizures. For some, epilepsy surgery is the best answer. In the past, epilepsy surgery meant a craniotomy, which requires a surgeon to open the patient's skull to remove the brain lesion causing epilepsy.

6 Mar 2012

Mayo Clinic experts available to discuss latest colorectal cancer research and treatment

March is National Colorectal Cancer Awareness Month. Colon cancer is one of the most common and deadly cancers, and also one of the most preventable. Mayo Clinic experts are available to discuss the latest in colorectal cancer research, detection and treatment.

6 Mar 2012

Cross Country Healthcare fourth quarter revenue increases 10% to $124.7M

Cross Country Healthcare, Inc. today reported revenue of $124.7 million in the fourth quarter ended December 31, 2011, a 10% increase from revenue of $113.7 million in the prior year quarter and a 5% decrease sequentially from the third quarter of 2011.

6 Mar 2012

PSI 2011 revenue up 25%

PSI, a full-service global CRO known for on-time patient enrollment and project delivery, announces 2011 results reporting record growth in new client wins and 25% year-over-year revenue increase.

6 Mar 2012

$Millennium commences MLN8237 phase 3 trial in relapsed or refractory PTCL$

Millennium commences MLN8237 phase 3 trial in relapsed or refractory PTCL

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of an international phase 3 clinical trial evaluating MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), an aggressive form of lymphoma.

5 Mar 2012

Astex fourth quarter total revenues increase to $21.2 million

Astex Pharmaceuticals, Inc., today reported financial results for the fourth quarter and year ended December 31, 2011.

5 Mar 2012

Zalicus completes reformulated Z160 Phase 1 clinical trial for pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.

5 Mar 2012

Thrombotech receives FDA IND approval for THR-18 Phase IIa clinical trial in stroke victims

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced Thrombotech Ltd., a portfolio company which Hadasit holds a 24% stake in, received an IND approval from the Food and Drug Administration enabling the initiation of a Phase IIa clinical trial in the U.S.

5 Mar 2012

Concert commences dosing in CTP-499 Phase 2 clinical trial for diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

5 Mar 2012

Repligen seeks EMA marketing approval for SecreFlo for pancreatic imaging

Repligen Corporation announced today that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for SecreFlo to improve detection of pancreatic duct abnormalities in patients with pancreatitis.

5 Mar 2012

BioLineRx granted Israeli approval for BL-7040 Phase II clinical trial for IBD

BioLineRx a biopharmaceutical development company, announced today that it has received approval from the Israeli Ministry of Health for commencing a Phase II clinical trial of BL-7040, an orally available molecule for treating Inflammatory Bowel Disease (IBD).

5 Mar 2012

FDA clears Covidien Solitaire FR revascularization device

Covidien, a leading global provider of healthcare products, today announced that the Solitaire FR revascularization device has been cleared by the U.S. Food and Drug Administration. The Solitaire FR device is intended to restore blood flow to the brain in patients suffering acute ischemic stroke by mechanically removing blood clots from blocked vessels.

5 Mar 2012

Rigosertib drug shows promise against advanced pancreatic cancer

The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication - and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don't rush are unharmed.

3 Mar 2012

Epicatechin-enriched cocoa shows promise against heart failure, Type 2 diabetes

A small clinical trial led by researchers at UC San Diego School of Medicine and VA San Diego Healthcare System (VASDHS) found that patients with advanced heart failure and type 2 diabetes showed improved mitochondrial structure after three months of treatment with epicatechin-enriched cocoa. Epicatechin is a flavonoid found in dark chocolate.

3 Mar 2012